Faculty, Department of Gastroenterology, A Caribbean Healthcare System, San Juan, Puerto Rico.
Gastroenterology Program Director, Department of Gastroenterology, VA Caribbean Healthcare System, San Juan, Puerto Rico.
P R Health Sci J. 2022 Sep;41(3):117-122.
The fecal immunohistochemical test (FIT) is a simple colorectal-cancer screening test. There are no recent studies evaluating the benefits of doing more than one a year. Our study aimed to evaluate the effectiveness of performing the test for 3 consecutive days in terms of detecting cancer and advanced adenomas.
This was a single-center retrospective review of records of patients who had daily tests for 3 consecutive days and had at least one positive during the period from 2009-2011.
A total of 456 records were reviewed, 410 met the inclusion criteria. Most of the participants were men (95.9%), with the mean age of all the participants being 64.3 (±7.8) years. Regarding the FIT results, 18.8% had positive results on all 3 tests, 20.2% had 2 positive tests, and 61.0% had 1 positive FIT. There were 16 (3.9%) patients in the studied sample that had colon cancer. Their lesions were located predominantly in the distal colon (ratio of distal to proximal: 2:1). The patients with 3 positive FITs had a higher prevalence of advanced adenomas (33.3% vs. 13.4%, respectively; P < .05).
Our study showed a low concordance between daily consecutive tests results. those patients with more than 1 positive FIT had a higher prevalence of advanced adenoma or adenocarcinoma than patients who had only one. Fewer than 4% of the patients in our study had colon cancer. Prospective studies would be needed to determine the effectiveness of more than 1 annual FIT in colon cancer prevention.
粪便免疫化学检测(FIT)是一种简单的结直肠癌筛查检测方法。目前尚无研究评估每年进行一次以上检测的获益。本研究旨在评估连续 3 天进行检测在检出癌症和高级腺瘤方面的效果。
这是一项对 2009 年至 2011 年期间连续 3 天每天进行检测且至少有一次检测结果阳性的患者的记录进行的单中心回顾性研究。
共回顾了 456 份记录,410 份符合纳入标准。大多数参与者为男性(95.9%),所有参与者的平均年龄为 64.3(±7.8)岁。就 FIT 结果而言,18.8%的患者 3 次检测结果均为阳性,20.2%的患者有 2 次阳性,61.0%的患者有 1 次阳性。在研究样本中有 16 例(3.9%)患者患有结肠癌。其病变主要位于远端结肠(远端与近端之比为 2:1)。3 次 FIT 阳性的患者高级腺瘤的发生率更高(分别为 33.3%和 13.4%;P<.05)。
我们的研究显示,连续 3 天的检测结果之间一致性较低。FIT 阳性结果超过 1 次的患者比仅 1 次阳性的患者高级腺瘤或腺癌的发生率更高。我们的研究中少于 4%的患者患有结肠癌。需要前瞻性研究来确定每年进行 1 次以上 FIT 在结直肠癌预防中的有效性。